Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2012
12/27/2012WO2012177970A1 Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
12/27/2012WO2012177924A2 Influenza virus mutants and uses therefor
12/27/2012WO2012177788A1 Modulators of 4-1bb and immune responses
12/27/2012WO2012177660A2 Leukotoxin e/d as a new anti-inflammatory agent and microbicide
12/27/2012WO2012177658A2 Methods of treating and preventing staphylococcus aureus infections and associated conditions
12/27/2012WO2012177653A2 Targeting the neuromuscular junction for treatment
12/27/2012WO2012177624A2 Focused radiation for augmenting immune-based therapies against neoplasms
12/27/2012WO2012177595A1 Compositions and methods for the therapy and diagnosis of cancer
12/27/2012WO2012177440A1 Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel
12/27/2012WO2012176876A1 Method for producing protein preparation
12/27/2012WO2012176779A1 Anti-erbb3 antibody
12/27/2012WO2012176765A1 Anti-human p-cadherin (cdh3) recombinant antibody
12/27/2012WO2012176582A1 Eye-drop-type vaccine for avian influenza
12/27/2012WO2012175692A1 Anti-axl antibodies and uses thereof
12/27/2012WO2012175691A1 Anti-axl antibodies and uses thereof
12/27/2012WO2012175613A1 NKp46-MEDIATED NK CELL TUNING
12/27/2012WO2012175518A1 Vaccine adjuvant composition comprising inulin particles
12/27/2012WO2012175222A1 AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES
12/27/2012WO2012174960A1 Detoxification tank and detoxification process after adsorption of tetanus vaccine
12/27/2012WO2012154587A3 Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
12/27/2012WO2012151272A3 T-cell vaccination with viral vectors via mechanical epidermal disruption
12/27/2012WO2012149265A3 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
12/27/2012WO2012142434A8 Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
12/27/2012WO2012141978A3 Formulations with reduced viscosity
12/27/2012WO2012139028A3 Anti-viral combination therapy
12/27/2012WO2012138911A3 Conjugates of anti-hiv drugs and somatostatin analogs
12/27/2012WO2012129375A3 Vaccination of sex reversed hybrid tilapia (oreochromis niloticus x o. aureus) with an inactivated vibrio vulnificus vaccine
12/27/2012WO2012129335A3 Hyd1 peptides for relapsed cancer
12/27/2012WO2012128508A3 Binding molecules capable of neutralizing the rabies virus, and uses thereof
12/27/2012WO2012127379A8 A method for the analysis of the evolution of gene sequences and for the forecast of an emerging viral strain
12/27/2012WO2012127352A3 Mia (melanoma inhibitory activity) inhibitors for detecting, preventing and curing vitiligo
12/27/2012WO2012125864A3 Overcoming resistance to erbb pathway inhibitors
12/27/2012WO2012125573A3 Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
12/27/2012WO2012122513A3 Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
12/27/2012WO2012115904A3 Production of n- and o-sialylated tnfrii-fc fusion protein in yeast
12/27/2012WO2012093137A9 Liposome formulation suitable for treating or preventing tuberculosis
12/27/2012WO2012085936A4 Recombinant respiratory syncytial virus plasmids and vaccines
12/27/2012WO2012078051A3 IPN Vaccine
12/27/2012WO2012058642A3 Use of sam68 for modulating signaling through the tnf receptor
12/27/2012WO2012012531A9 Compositions and methods featuring il-6 and il-21 antagonists
12/27/2012WO2011022633A3 Method of threating cancer
12/27/2012US20120329990 B7-related nucleic acids and polypeptides useful for immunomodulation
12/27/2012US20120329706 Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof
12/27/2012US20120329671 Methods of identifying obm modulators
12/27/2012US20120329670 Epitope testing using soluble hla
12/27/2012US20120329063 Novel means for the diagnosis and therapy of ctcl
12/27/2012US20120328702 Nanoparticle compositions
12/27/2012US20120328701 Nanoparticle compositions, formulations thereof, and uses therefor
12/27/2012US20120328691 Anilinopiperazine derivatives and methods of use thereof
12/27/2012US20120328688 Biocompatible film with variable cross-sectional properties
12/27/2012US20120328667 In situ constituting a vaccine for administration to a predetermined herd of animals
12/27/2012US20120328662 Composition for inhibiting tumor cell proliferation
12/27/2012US20120328660 Immunogenic compositions useful in provoking an integrated response to tumor antigens
12/27/2012US20120328659 Treatment of streptococcal infections
12/27/2012US20120328658 Compositions and methods for vaccinating against hsv-2
12/27/2012US20120328657 Compositions and methods for vaccinating against hsv-2
12/27/2012US20120328655 Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
12/27/2012US20120328654 Multi-phase emulsions based on amphiphilic block copolymers
12/27/2012US20120328653 Modified immunization vectors
12/27/2012US20120328652 Recombinant attenuated parvovirus
12/27/2012US20120328651 Chimpanzee adenovirus vaccine carriers
12/27/2012US20120328650 Modified vaccinia ankara virus variant
12/27/2012US20120328649 Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus
12/27/2012US20120328646 Globo H and Related Anti-Cancer Vaccines with Novel Glycolipid Adjuvants
12/27/2012US20120328645 Malaria Vaccines
12/27/2012US20120328644 Low Antigen-dose Immunization for Maximizing T-helper Cell 1 (Th1) Immunity Against a Pathogen
12/27/2012US20120328643 Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
12/27/2012US20120328642 Botulinum neurotoxin antigenic compositions and methods
12/27/2012US20120328641 Conformationally stabilized hiv envelope immunogens
12/27/2012US20120328640 Methods and compositions for the treatment and prevention of cancer
12/27/2012US20120328639 Immunogenic lhrh compositions and methods relating thereto
12/27/2012US20120328638 Mybl2 peptides and vaccines containing the same
12/27/2012US20120328637 Methods and compositions for modulating the activity of the interleukin-35 receptor complex
12/27/2012US20120328636 Kdr peptides and vaccines comprising the same
12/27/2012US20120328635 Chaperonin 10 variants
12/27/2012US20120328634 Immunoconjugates with an Intracellularly-Cleavable Linkage
12/27/2012US20120328633 T cell activation inhibitor, pharmaceutical composition containing same, and screening method for t cell activation inhibiting substance
12/27/2012US20120328632 Inhibition of leukocyte adhesion
12/27/2012US20120328631 Ep1 inhibition
12/27/2012US20120328630 Methods for treating and/or limiting development of diabetes
12/27/2012US20120328629 Therapeutic Applications Targeting SARM1
12/27/2012US20120328628 Antibodies to conformationally trapped proteins
12/27/2012US20120328627 Chemokine receptor antagonists and use thereof
12/27/2012US20120328626 Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
12/27/2012US20120328625 Targeted binding agents directed to sonic hedgehog homolog and uses thereof
12/27/2012US20120328624 Anti-dll3 antibody
12/27/2012US20120328623 ANTI-erbB3 ANTIBODY
12/27/2012US20120328622 Novel compounds
12/27/2012US20120328621 Immunogens, compositons and uses thereof, method for preparing same
12/27/2012US20120328620 Epidermalgrowth factor receptor mutations
12/27/2012US20120328619 Trispecific Therapeutics Against Acute Myeloid Leukaemia
12/27/2012US20120328618 Dosage regimen for administering a cd19xcd3 bispecific antibody
12/27/2012US20120328617 Method for inhibiting angiogenesis
12/27/2012US20120328616 Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor
12/27/2012US20120328615 Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
12/27/2012US20120328614 Immunoglobulin Formulation and Method of Preparation Thereof
12/27/2012US20120328613 Humanized anti-factor d antibodies and uses thereof
12/27/2012US20120328612 Anti-flt3 antibodies and methods of using the same
12/27/2012US20120328611 Substituted triazolopyridines
12/27/2012US20120328610 Triazolopyridines
1 ... 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 ... 1823